EPO and infarction: One such agent, erythropoietin (EPO), has already been successful in the clinic for reduction of cell death and remodeling post MI (Brines and Cerami, 2008) and has shown benefits in experimental infarction when delivered using a gelatin cardiac patch (Kobayashi et al., 2008).